Risk factors for venous thromboembolism in adolescents in South Moravian region, Czech Republic within years 2004–2010

Česká verzia

Authors: O. Zapletal; V. Fiamoli; J. Blatný; S. Köhlerová; J. Švancara ¹
Authors place of work: Oddělení dětské hematologie, Centrum pro trombózu a hemostázu, Masarykova univerzita a FN Brno, primář MUDr. J. Blatný, Ph. D., Institut biostatistiky a analýz, Masarykova univerzita, Brno, ředitel doc. RNDr. L. Dušek, Dr. ¹
Published in the journal: Čes-slov Pediat 2012; 67 (2): 89-94.
Category: Original Papers

Summary

Venous thromboembolism (VTE) is relatively uncommon in adolescent age. In our survey we evaluate presence of particular risk factors for VTE in 72 consecutive patients aged 14 to 18 years, who were treated for their first VTE episode at our department in 7 years period (2004–2010).

In median, our patients had 2 risk factors (RF) (range 0–5 RF/patient), more often acquired ones. Most frequent RF were: high FVIII in 44 %, combined oral hormonal contraception (42 % of all, but 65% of girls), FV Leiden 28 %, injury 19 % and infection 18 %. We also recorded thrombosis location – 50 % patients had deep vein thrombosis in distal lower extremities veins and 28 % ileofemoral thrombosis. Other locations were much less frequent. 11 % patients had pulmonary embolism, one girl died. Annual incidence of VTE in our region has been calculated relatively high – 15.6 per 100000 adolescents.

This finding supports increasing occurrence of VTE in adolescents, as well as expected distribution of particular RF for VTE. Acquired RF were behind VTE in more then 80 % of events in our cohort.

Key words:
thrombosis, adolescent, risk factors

Zdroje

1. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158 (6): 585–593.

2. The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Office of the Surgeon General (US); National Heart, Lung, and Blood Institute (US). Rockville (MD): Office of the Surgeon General (US); 2008.

3. Schneppenheim R, Greiner J. Thrombosis in infants and children. Hematology Am Soc Hematol Educ Program 2006: 86–96.

4. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000 Jun; 47 (6): 763–766.

5. Blatný J. Kdy vyšetřovat vrozená trombofilní rizika u dětí? Transfuze Hematol dnes 2011; 17 (2): 69–71.

6. Raffini L, Huang YS, Witmer C, et al. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics 2009 Oct; 124 (4): 1001–1008.

7. Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010 Jul; 126 (1): 5–11.

8. Tchaikovski SN, van Vliet HA, Thomassen MC, et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 2007 Dec; 98 (6): 1350–1356.

9. Spentzouris G, Scriven RJ, Lee TK, et al. A review of pediatric venous thromboembolism in relation to adults. J Vasc Surg 2011 Sep 22.

10. Kreuz W, Stoll M, Junker R, et al. Familial elevated factor VIII in children with symptomatic venous thrombosis and post-thrombotic syndrome: results of a multicenter study. Arterioscler Thromb Vasc Biol 2006 Aug; 26 (8): 1901–1906.

11. Hirsh J. Guidelines for Antithrombotic Therapy. 8th ed. Hamilton: 2008.

12. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005; 3 (8): 1611–1617.

13. Poul H. Trombofilní stavy významné v patogenezi žilní tromboembolické nemoci. www.thrombosis.cz.

14. Dulíček P. Kontraceptiva a tromboembolické příhody. Tempus Medicorum 2012; 1: 18–22.